When does the patent for Octreotide expire?

Overview of Octreotide

Octreotide is a synthetic analogue of the naturally occurring peptide hormone somatostatin. Somatostatin plays a critical role in regulating endocrine and exocrine secretions. Unlike its endogenous counterpart, octreotide exhibits a longer half-life and a more potent inhibitory mechanism on the secretion of growth hormone, thyroid-stimulating hormone, and various gastrointestinal peptides. This pharmacological profile makes octreotide particularly useful in the treatment of conditions characterized by overproduction of these hormones, where quick and sustained suppression is clinically advantageous.

Medical Uses and Benefits 
Medically, octreotide has been pivotal in treating several conditions. It is widely used in managing acromegaly, where it helps suppress excessive growth hormone secretion, leading to improvements in symptoms and quality of life. In addition, octreotide is employed in the management of carcinoid syndrome, where its ability to inhibit hormone secretion alleviates symptoms such as flushing and diarrhea. Further applications include managing hyperinsulinism in infants and adults, as well as being utilized in the treatment of idiopathic intracranial hypertension. Because of its efficacy in a range of pathophysiological states, octreotide has become a reference drug within its class.

Patent Details of Octreotide

Original Patent Information 
The primary patent reference for octreotide is provided by the patent document titled “Pharmaceutical compositions containing octreotide and excipients for oral or rectal administration.” This patent, assigned to NOVARTIS AG, was filed on January 25, 1993, and published on February 28, 1995. Critically, the patent contains an explicit expiration date—February 28, 2012. The focus of this patent is on novel pharmaceutical compositions that incorporate octreotide alongside various excipients, specifically designed to enhance the resorption properties when administered orally or rectally. This patent represents a pivotal milestone, as it covers a significant application method for octreotide beyond the traditional injection route, thereby broadening the scope of therapeutic delivery.

Patent Extensions and Variations 
Beyond the original patent reference, additional patent filings have been made internationally and across various jurisdictions that relate to octreotide. Some patents cover alternative manufacturing processes and formulations—for instance, patents describing processes for the preparation of octreotide and its amorphous form exist. These additional patents may have their own filing, publication, and expiration dates, thereby complementing the basic composition patent by NOVARTIS AG. Nonetheless, when addressing the question of "When does the patent for Octreotide expire?" the most definitive and directly cited data from the reliable synapse source indicates that the primary patent expires on February 28, 2012. This expiration date pertains specifically to the composition patent developed by NOVARTIS AG, and it is essential to note that while improvements and new formulations may be under separate intellectual property protections, the original composition patent's life cycle was clearly defined with a termination in early 2012.

Implications of Patent Expiration

Market Impact 
The expiration of a key patent such as the one for octreotide can have significant market implications. When a patent expires, the exclusive market rights held by the innovator—NOVARTIS AG in this instance—are no longer legally enforceable. This event typically triggers a period wherein generic manufacturers are legally permitted to produce equivalent versions of the medication. Given that the pivotal composition patent for octreotide expired on February 28, 2012, the generic pharmaceutical market has been able to introduce lower-cost alternatives, thereby intensifying competition in the market. 
Generic competition generally leads to reduced drug prices, which in turn can increase accessibility for patients. However, patent expirations also challenge the original innovator companies to either innovate further, pursue new delivery mechanisms, or extend their market exclusivity through additional patents on improved or modified formulations.

Generic Drug Availability 
Following the expiration of the octreotide patent in 2012, the market experienced a surge in the availability of generic versions. The generic versions typically provide comparable pharmacological efficacy at a significantly lower cost, thereby increasing options for healthcare providers and lowering overall healthcare expenditures. This increased competition has implications for market share dynamics where the original branded product may see a decrease in its market dominance as generics capture a larger portion of the market. 
Moreover, generics entering the market post-patent expiration encourage a more competitive environment, which often prompts price reductions and better cost-efficiency for patients. This is particularly critical in therapeutic areas where long-term treatment is necessary, such as in the management of acromegaly or carcinoid syndrome.

Effects on Treatment Costs and Access 
One of the primary benefits of patent expiration is the reduction in treatment costs. When the exclusive rights lapse, the reduction in monopoly pricing allows generics to be priced more competitively. In many therapeutic areas, including endocrinology and oncology, this transition facilitates broader patient access to necessary medications. 
For octreotide, the expiration in 2012 has meant that patients requiring long-term management with synthetic somatostatin analogues can now benefit from lower-cost alternatives without compromising on efficacy. This reduction in cost has significant implications for healthcare systems, particularly in settings where budget constraints limit access to expensive, patented medications. 
Additionally, the competitive landscape created by generic entries may drive further improvements in the production processes and new formulation strategies, which can indirectly lead to enhanced drug stability, better patient compliance, and further cost reductions in subsequent years.

Future Considerations

Research and Development Post-Expiration 
The expiration of the key octreotide patent opened avenues not only for generic competition but also for further innovation by the original innovator and other companies. Following the patent expiration, the focus of research and development often shifts to developing next-generation formulations, alternative delivery methods, or new indications. For instance, while the original patent for octreotide expired in 2012, newer oral formulations such as Mycapssa® have been developed and patented to offer improved patient convenience and compliance. 
This trend demonstrates that while the foundational patent rights cease, market exclusivity may be extended through strategic R&D efforts and subsequent patent filings covering innovative delivery systems, improved bioavailability, or tailored therapeutic applications. This cycle of innovation not only revives the brand’s market position but also ensures continued support for long-term research in the area of peptide therapeutics.

Potential Competitors and Alternatives 
Post-patent expiration, the market landscape typically becomes fertile ground for the entry of new competitors. Generic drug manufacturers along with biosimilar companies (particularly relevant for biopharmaceuticals) step in to fill the market gap left by the loss of exclusivity. In the case of octreotide, after 2012, various companies have been able to legally produce and market generic versions of the drug, intensifying competition and leading to progressive price adjustments. 
Furthermore, competition is not confined merely to generic versions of octreotide; there is active exploration into other somatostatin analogues and related compounds that aim to address similar therapeutic indications. This broadening of therapeutic options not only benefits patients but also stimulates further research in the domain of hormone regulation, potentially leading to better, more cost-effective treatment alternatives in the future.

Detailed Conclusion

In summary, based on the authoritative and structured patent data available from the synapse database, the primary patent covering pharmaceutical compositions containing octreotide was filed by NOVARTIS AG on January 25, 1993, published on February 28, 1995, and is set to expire on February 28, 2012. This key piece of intellectual property has played a central role in defining the market exclusivity and application methods for octreotide. 

- The original patent details focused on novel formulations designed to enhance resorption for oral or rectal administration, extending the therapeutic options beyond conventional injectable forms. With an explicit expiration date of February 28, 2012, the expiry of this patent has profound implications across multiple dimensions of the pharmaceutical market. 
- From a market impact perspective, its expiration has triggered the entry of generic manufacturers, leading to increased market competition, significantly lower prices, and broader patient accessibility. The availability of generics post-2012 has reduced treatment costs and provided more affordable options for patients requiring long-term management of conditions such as acromegaly, carcinoid syndrome, and hyperinsulinism. 
- In terms of treatment costs, this transition from a patented monopoly to a competitive market has resulted in economic benefits that improve overall access to essential medications. 
- Looking ahead, the expiration has also spurred new research and development efforts. Companies have pursued novel delivery methods and improved formulations—such as the oral octreotide capsules currently represented by products like Mycapssa®—to extend market exclusivity in innovative ways. Moreover, the evolving competitive dynamics have created space for alternative somatostatin analogues and related therapies to emerge, ensuring that patients have a broader range of treatment options available. 

Ultimately, the expiration of the octreotide patent in 2012 marked a significant shift in both innovation and market structure in the field of peptide therapeutics. It not only underscores the natural lifecycle of pharmaceutical patents but also highlights the importance of continual innovation, as companies strive to enhance therapeutic efficacy and accessibility in the wake of generic competition. This dynamic interplay between patent protections, market competition, and ongoing R&D will likely continue to shape the landscape of pharmaceutical treatments, benefiting patients and driving further advances in medical science.

In conclusion, the patent for octreotide expired on February 28, 2012. This expiration has reshaped the market by enabling generic competition, reducing drug costs, and prompting further innovations in drug formulation and delivery—all of which serve to improve patient outcomes and expand therapeutic options.

For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！